Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU-NK-101 in relapsed/refractory acute myeloid leukemia
NCT05470140Phase 1Completed
- Sponsor
- Wugen
- Start
- Jul 2023
- Primary completion
- Oct 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of WU-NK-101 in acute myeloid leukemia (AML), sponsored by Wugen. Primary endpoints: Adverse Events at 24 months and Maximum Tolerated Dose at 21 days. Started Jul 2023; status: completed.
02
Drugs
WU-NK-101
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05470140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470140.